Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 29, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
马萨诸塞州剑桥-（BUSINESS WIRE）-2024年11月29日-领先的罕见病精准遗传医学企业sarepta therapeutics公司（纳斯达克股票代码：SRPT）向其于2024年11月29日（“授予日期”）雇佣的14名员工授予了股权奖励，这些奖励此前已获得了董事会薪酬委员会在sarepta的2024年雇佣开始激励计划下的批准，作为对这些员工就职的重要诱因。这些股权奖励是根据纳斯达克上市规则5635(c)(4)批准的。
The employees received in the aggregate 8,040 restricted stock units ("RSUs"). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee's continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta's common stock.
员工们共收到了8,040个限制性股票单位（“RSUs”）。每年在授予日期的每个周年，这些RSUs中的四分之一将获得一次激励，使得每名员工获得的RSUs在授予日期的第四周年将完全获得激励，在每种情况下，前提是该雇员在该激励日期依然与sarepta公司保持雇佣关系。员工们没有收到买入sarepta公司普通股的期权。
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
关于Sarepta Therapeutics
Sarepta紧急任务：为破坏生活和砍短未来的罕见疾病而工程化精准基因医学。我们在杜兴肌肉萎缩症（DMD）和肢带肌肉萎缩症（LGMD）方面拥有领先地位，目前正在开发超过40个处于不同阶段的项目。我们庞大的研发管线，由多平台精准基因医学引擎驱动，涵盖基因疗法、RNA和基因编辑。欲了解更多信息，请访问 链接 并关注我们的 领英，X（曾为Twitter），Instagram和Facebook账户。
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at . We encourage investors and potential investors to consult our website regularly for important information about us.
信息的互联网发布
我们会定期在网站的“投资者”版块发布可能对投资者重要的信息。我们鼓励投资者和潜在投资者定期查阅我们的网站以了解我们的重要信息。
Source: Sarepta Therapeutics, Inc.
来源：Sarepta Therapeutics，Inc。
View source version on businesswire.com:
在businesswire.com上查看源版本：
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
投资者联系人：
Ian Estepan，617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
媒体联系：
Tracy Sorrentino，617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
来源：Sarepta Therapeutics，Inc。
